Advanced Bifurcation Systems (ABS or the Company), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company is planning to undertake human clinical trials in New Brunswick, Canada.  The planning for these clinical trials has been initiated with the participation of Dalhousie University’s Medical School (DMNB), Horizon Health Network (HHN) where the New Brunswick Heart Center is located, and the New Brunswick Health Research Foundation (NBHRF). The introduction to these institutions was spearheaded by Opportunities NB.

Dr. Mehran Khorsandi, Chairman and Founder of Advanced Bifurcation Systems stated in a press release, “ABS is very excited about commencing clinical trials within the New Brunswick health care system. The high quality of the interventional cardiologists, combined with the excellence of the New Brunswick health care system and the institutions that support it, will provide a great resource for us when we initiate our clinical trials.”

Mr. Charles Laverty, Chief Executive Officer of Advanced Bifurcation Systems commented, “We believe the quality of the data from the clinical trials will mirror the strong reputation of outcomes within the New Brunswick health care system and look forward to working with this outstanding team.”

"The NBHRF facilitates and supports the Health Research Enterprise in New Brunswick.  We are pleased to witness the interest and commitment of ABS in medical device innovation as well as recognizing the expertise of the Specialists and health professionals at the NBHC and the HHN Research Services.  The conduct of clinical research and clinical trials in New Brunswick is a great testament to our efforts at building out our health research capacity," says Dr. Bruno Battistini, President, CEO and Scientific Director of the New Brunswick Health Research Foundation.   

“ONB is always looking at how to leverage New Brunswick’s strengths to bring new opportunities here that will generate economic growth and skilled jobs for New Brunswickers,” said ONB CEO Stephen Lund. “This province has world-class assets in the health-research sector, and it is drawing interest from innovative companies like Advanced Bifurcation Systems (ABS) Inc. We are excited to see what ABS can achieve in New Brunswick.”

Upon successful completion of the human clinical trials, ABS intends to establish a manufacturing facility in New Brunswick, to serve ABS’s customers globally. ABS has incorporated a Canadian subsidiary, Advanced Bifurcation Systems Canada, Inc. to support this effort.